GYNO-DAKTARIN 400mg price in UAE

Overview

Welcome to Dwaey, specifically on GYNO-DAKTARIN 400mg Vaginal Ovules page.
This medicine contains an important and useful components, as it consists of Miconazole (as nitrate).
GYNO-DAKTARIN 400mg is available in the market in concentration 400mg/Ovule and in the form of Vaginal Ovules.

JANSSEN PHARMACEUTICA N.V. is the producer of GYNO-DAKTARIN 400mg and it is imported from BELGIUM, The most popular alternatives of GYNO-DAKTARIN 400mg are listed downward .

Mode Of Action

Miconazole inhibits ergosterol synthesis thus damaging fungal cell wall membrane and increases its permeability, allowing leakage of nutrients.

Indication

Oropharyngeal & Esophageal Candidiasis.

Precaution

Discontinue if sensitization or irritation occurs. Pregnancy and lactation. Lactation: Unknown whether distributed in breast milk, caution advised

Side Effects

1-10% Diarrhea (6%)
Nausea (4.6%)
Headache (5%)
Dysgeusia (2.9%)
Upper abdominal pain (2.5%)
Vomiting (2.5%)

Contra indication

Hypersensitivity; hepatic impairment. Porphyria.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine. Potentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.